In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Diagnostic performance of global and segmental T2, native T1 and ECV mapping in patients with clinical acute myocarditis

Session Poster session 1

Speaker Emmanuelle Vermes

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : T1 and T2 Mapping, T2*
  • Session type : Poster Session
  • FP Number : P173

Authors : EV Vermes (Tours,FR), SC Coulibaly (Tours,FR), JP Pucheux (Tours,FR), DB Babuty (Tours,FR), LB Brunereau (Tours,FR), HD Daurel (Tours,FR)

EV Vermes1 , SC Coulibaly1 , JP Pucheux1 , DB Babuty1 , LB Brunereau1 , HD Daurel1 , 1University Hospital of Tours - Tours - France ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii131

Background: The detection of focal myocardial injury on T2 weighted images and late gadolinium enhancement (LGE) are criteria for the diagnosis of myocarditis. More recently, T2 and T1 mapping have emerged as promising techniques to detect myocardial injury.

This study was conducted to test the diagnostic performance of global and segmental T2, native T1 and ECV mapping in a large single-center cohort of patients with clinical acute myocarditis.

Method: Cardiac magnetic resonance (CMR) was prospectively performed in 69 patients with suspected myocarditis (within 5 days of the onset of symptoms and after 3 –month follow up) and 45 controls. Images were acquired on a 1.5 Tesla scanner including T2 mapping (T2 prepared-SSFP) and T1 mapping using a modified look locker inversion recovery sequence ( MOLLI) at, mid level in short axis view. Segmental analysis was performed by tracing a ROI in 6 segments of the myocardium according to the AHA segmentation.

T2 and T1 values were measured before and 15 minutes (for T1 mapping) after contrast administration. LGE images were acquired in short and long axis view. The results are expressed by the median and the 5th and the 95th percentiles.

Results:  Patients with myocarditis had significantly higher global T2, native T1 and ECV values: 53ms [51-57] vs 51 [49-53] (p<0.001); 1009 ms [969-1034] vs 963 [946-972] (p<0.001) and 33.8% [32.2-35.4] vs 23 [21.7-25.2] (p<0.001) respectively.  The sensitivity, specificity and area under the curve (AUC) for T2 (cutoff 54ms) were 49%, 89% and 0.71 respectively; for native T1 (cutoff 979ms) were 66% and 84% and 0.76 respectively and for ECV (cutoff 28%) were 76%, 100% and 0.84 respectively.

Out of 69 patients, LGE was absent in 11 patients. However, T2, native T1 and ECV values were significantly higher in these 11 patients compared to controls.

Segmental analysis showed that T2, native T1 and ECV mapping were significantly higher in all segments of the left ventricle. However, these 3 parameters do not provide better diagnostic performance than the global analysis.

At 3 month-follow up, T2,  native T1 and ECV indexes were significantly lower compared to  the acute phase and were not significantly different from the control group

Conclusion: Global ECV provide the best diagnostic performance in adults with suspected  acute  myocarditis.  Segmental analysis of T2, T1 and ECV indexes demonstrated that myocarditis is a diffuse process involving all segments of the myocardium either LGE is present or absent. Further studies are required to confirm these data.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are